"In conclusion, the implementation of a rapid quantitative hCG POC method has significantly reduced the time to the results and the LOS in a gynecology ED, with a connection to the middleware ensuring the traceability of the results and allowing for quality management via the central lab."

"While the cTnI POCT showed analytical performance comparable to CLT, the results of the cTnT assay on the same device did not suffice to determine a reliable 99th percentile. The present evaluation supports the usage of the cTnI POCT, but application of the cTnT POCT needs further evaluation."

"Additional use of ultrasensitive copeptin improves diagnostic performance of conventional sensitive POCT assays overcoming lower sensitivities at the cost of a drop of clinical specificity. When hsTn is temporarily unavailable, copeptin and POCT for cTn may allow initial evaluation at a comparable performance as hsTnT at admission."

"We confirmed the manufacturer recommended 99th percentile cutoff of 23 ng/L and established a CV of 6.7% at 20 ng/L. These results demonstrated that the POC assay AQT90 FLEX cTnI must be classified as "guideline acceptable"."

Integrating Statistical Quality Control (SQC) into Point of Care Testing (PoCT) enables an ISO 22870-compliant, risk-based approach to quality management. By using Sigma-metrics to assess analytical robustness, laboratories can replace rigid QC schedules with individualized plans. This strategy optimizes IQC frequency, ensuring that resources are directed toward the most critical parameters and balancing operational efficiency with patient safety.

"These findings emphasize that the clinical application of POC troponin assays [Atellica VTLi, i-STAT, AQT System. Cobas h 232, CArdio3] in AMI diagnosis must consider the test’s robust specificity (≈90%) alongside its limited sensitivity (<50%)."

"Both hCG POCT devices [i-STAT 1 (Abbott), AQT 90 FLEX (Radiometer)] were verified for use in clinical practice. Practical factors must also be considered when choosing which device to use in each unit."

"The AQT90 FLEX PCT assay demonstrated excellent analytical performance and diagnostic agreement with the Cobas E602 assay, allowing both stand-alone and side-by-side testing. The other assays [Getein 1100, mLabs, and Finecare] demonstrated some analytical deficiencies, potentially limiting their diagnostic use. Any clinical use of PCT results should always be in combination with all other clinical signs and diagnostic information."

"At best, the semi-quantitative CRP strips [Actim and Cleartest] could be used to discriminate between normal and increased levels of CRP. Of the quantitative methods [Afinion, QuikRead go, Smart, iChroma, Microsemi and AQT90 Flex], when combining analytical with practical evaluation, the Smart and Afinion would be the preferred analyzers for POCT."

"Overall, the AQT90 hCG assay performed well [method comparisons were done against Abbott i-STAT Total βhCG, Beckman Coulter Total βhCG (5th IS), and Roche hCG+β] and would be suitable for smaller suburban or rural hospitals. Some limitations have been noted and should be kept in mind during clinical testing."

"The laboratory-based Roche Modular E170 hs-cTnT using the 0 h/1 h algorithm is reliable and accurate method for diagnosing NSTEMI in undifferentiated chest pain patients presenting to the ED. POCT cTnT assay has comparable diagnostic accuracy to the hs-cTnT assay and its rapid turnaround time makes it a valuable tool in expediting the diagnostic workup of chest pain patients."

"Our study provides the procedure and essential data to guide selection of a POC cTn device. Of the point‐of‐care devices, methods evaluated Radiometer AQT90 (cTnI and cTnT) and Pathfast might be considered."

"This study has validated the performance of a POCT Trop-I assay against a central laboratory immunoassay and found acceptable results. POCT assays for cTnI should be implanted in emergency settings to ensure the fast triage of patients with chest pain, as well as timely diagnosis."

"PATHFAST™ cTnI assay proved itself as comparable to ESC-guideline acceptable hs-cTn assays. The lower sensitivity of the other POC assays [AQT90 FLEX cTnI and cTnT; Stratus CS 200 cTnI; and Triage MeterPro cTnI] limits their clinical utility and would require longer follow-up monitoring of patients for the safe NSTEMI rule-out."

"The comparison of two different assays of cTnI against a diagnosis of acute MI (AMI) shows that both assays behave equally well with a high degree of sensitivity and specificity. The resulting "best cut-off" suggests that this AQT90 FLEX cTnI concentration could be evaluated as the potentially new "clinically usable" cut-off for AMI/myocardial necrosis diagnoses."

"The AQT90-flex POCT cTnT assay is not yet sensitive and reliable enough to be used to exclude AMI in the ED with a single blood draw at the time of presentation in the ED, and therefore, may have limited applicability in the ED setting."

"In non-selected population, the cTnT AQT Flex© assay on AQT90© with kinetic change at 3h, provides similar clinical classification of patients, particularly for AMI group as compared to central laboratory hs-cTnT assay and could be suitable for clinical use."

"It is recommended to use a slope of 4.9524 and an intercept of 0.003 to adjust the TnI values of the AQT90 FLEX to the UniCel DxI 800 assay systems. Clinically relevant, i.e., significant TnI changes (rise or fall), can be reliably interpreted by accounting for the disparate results and the imprecision profile of the TnI assay method by applying the mathematical relationship described by Reed."

"Nt-proBNP testing with the AQT 90 FLEX analyzer is comparable to the central lab assay and may offer the advantages of POCT testing for the diagnosis and prognosis of heart failure."

"POCT delivers D-dimer results in significantly shorter turnaround times than pathology services; however, poor bioequivalence between VIDAS and POCT raises the issue of acceptability for use in the ED."

The AQT90 FLEX® PCT assay demonstrates excellent analytical performance and aligns with ISO 15189:2012 standards. With a strong correlation ($r \geq 0.990$) to the reference method and clinically insignificant bias, it provides reliable results for both macro- and microtubes. Additionally, the 24-hour stability of PCT at room temperature makes the AQT90 FLEX® an ideal point-of-care solution for rapid, whole-blood testing in pediatric and emergency settings.